<--- Back to Details
First PageDocument Content
Pharmaceutical industry / Medicine / Multiple sclerosis / Cladribine / Purines / European Medicines Agency / Glatiramer acetate / Clinical trial / Committee for Medicinal Products for Human Use / Pharmacology / Health / Clinical research
Date: 2013-07-21 06:10:18
Pharmaceutical industry
Medicine
Multiple sclerosis
Cladribine
Purines
European Medicines Agency
Glatiramer acetate
Clinical trial
Committee for Medicinal Products for Human Use
Pharmacology
Health
Clinical research

Movectro Q&A reexamination

Add to Reading List

Source URL: www.ema.europa.eu

Download Document from Source Website

File Size: 50,11 KB

Share Document on Facebook

Similar Documents

November 12, 2014 Dear Colleagues, Please find below details of a high priority clinical study just opened to patient accrual at the Northwestern Medicine Developmental Therapeutics Institute (NMDTI). A Pivotal Multicent

November 12, 2014 Dear Colleagues, Please find below details of a high priority clinical study just opened to patient accrual at the Northwestern Medicine Developmental Therapeutics Institute (NMDTI). A Pivotal Multicent

DocID: 1aF51 - View Document

[PRODUCT NAME]  [Dose Form]

[PRODUCT NAME] [Dose Form]

DocID: 14SOe - View Document

Cladribine  Chemotherapy Information: Cladribine Medication information leaflet for

Cladribine Chemotherapy Information: Cladribine Medication information leaflet for

DocID: 11tvl - View Document

2-Chloro-2’-deoxyadenosine 2-CdA, Cladribine 9-(2’-Deoxy-β-D-ribofuranosyl)-2-chloro-adenine Cat. No.

2-Chloro-2’-deoxyadenosine 2-CdA, Cladribine 9-(2’-Deoxy-β-D-ribofuranosyl)-2-chloro-adenine Cat. No.

DocID: Q5rN - View Document

PDF Document

DocID: yrY9 - View Document